Results 41 to 50 of about 63,989 (248)

Rivaroxaban versus warfarin for the management of left ventricle thrombus

The Egyptian Heart Journal, 2021
Background Rivaroxaban has been recently introduced for the management of non-valvular intra-cardiac thrombosis with variable results. We aimed to compare the results of the off-label use of rivaroxaban versus warfarin in the management of patients with ...
Monirah A. Albabtain, Yahya Alhebaishi, Ola Al-Yafi, Hatim Kheirallah, Adel Othman, Haneen Alghosoon, Amr A. Arafat, Ahmed Alfagih   +7 more
doaj   +1 more source

Thromboprophylaxis for Children Post‐Fontan Procedure: Insights From the UNIVERSE Study

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2021
Background Patients with single‐ventricle physiology who undergo the Fontan procedure are at risk for thrombotic events associated with significant morbidity and mortality.
Brian W. McCrindle, Alan D. Michelson, Andrew H. Van Bergen, Estela Suzana Horowitz, Juan Pablo Sandoval, Henri Justino, Kevin C. Harris, John L. Jefferies, Liza Miriam Pina, Colleen Peluso, Kimberly Nessel, Wentao Lu, Jennifer S. Li   +12 more
doaj   +1 more source

Safety and Efficacy of Vitamin K Antagonists versus Rivaroxaban in Hemodialysis Patients with Atrial Fibrillation: A Multicenter Randomized Controlled Trial

Journal of the American Society of Nephrology, 2021
Visual Abstract Significance Statement Direct oral anticoagulants (DOACs) have a superior risk-benefit profile compared with vitamin K antagonists (VKAs) in patients with normal renal function or early stage CKD, but whether this can be extended to the ...
A. D. De Vriese, R. Caluwé, Hans Van Der Meersch, K. De Boeck, D. De Bacquer   +4 more
semanticscholar   +1 more source

Safety of Proton Pump Inhibitors Based on a Large, Multi-year, Randomized Trial of Patients Receiving Rivaroxaban or Aspirin.

Gastroenterology, 2019
BACKGROUND & AIMS Proton pump inhibitors (PPIs) are effective at treating acid-related disorders. These drugs are well tolerated in the short term, but long-term treatment was associated with adverse events in observational studies.
P. Moayyedi, J. Eikelboom, J. Bosch, S. Connolly, L. Dyal, O. Shestakovska, D. Leong, Sonia S Anand, S. Störk, K. Branch, Deepak L. Bhatt, P. Verhamme, M. O’Donnell, A. Maggioni, E. Lonn, L. Piegas, G. Ertl, M. Keltai, N. C. Bruns, E. Muehlhofer, G. Dagenais, Jae‐Hyung Kim, M. Hori, P. Steg, R. Hart, R. Diaz, M. Alings, P. Widimsky, Á. Avezum, J. Probstfield, Jun Zhu, Yan Liang, P. López-Jaramillo, A. Kakkar, A. Parkhomenko, L. Rydén, N. Pogosova, A. Dans, F. Lanas, P. Commerford, C. Torp-Pedersen, T. Guzik, D. Vinereanu, A. Tonkin, B. Lewis, C. Félix, K. Yusoff, K. Metsarinne, K. Fox, S. Yusuf   +49 more
semanticscholar   +1 more source

Blood loss in primary total knee arthroplasty-body temperature is not a significant risk factor-a prospective, consecutive, observational cohort study [PDF]

, 2015
BACKGROUND: Hypothermia related to anaesthesia and operating theatre environment is associated with increased blood loss in a number of surgical disciplines, including total hip arthroplasty.
Beller, Elaine, Dan, Michael, Jones, Peter, Liu, David, Martos, Sara Martinez, Randle, Ray   +5 more
core   +2 more sources

In vivo evaluation of the pharmacokinetic interactions between almonertinib and rivaroxaban, almonertinib and apixaban

Frontiers in Pharmacology, 2023
Background: Almonertinib, a third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), is commonly used as a first-line treatment for non-small cell lung cancer (NSCLC) patients with EGFR T790M mutations.
Zhi Wang, Ying Li, Xueru He, Yuhao Fu, Yajing Li, Xin Zhou, Zhanjun Dong   +6 more
doaj   +1 more source

Rivaroxaban treatment for six weeks versus three months in patients with symptomatic isolated distal deep vein thrombosis: randomised controlled trial

British medical journal, 2022
Objective To compare two different treatment durations of rivaroxaban in patients with symptomatic isolated distal deep vein thrombosis (DVT). Design Randomised, double blind, placebo controlled clinical trial.
W. Ageno, L. Bertù, E. Bucherini, G. Camporese, F. Dentali, M. Iotti, G. Lessiani, R. Parisi, P. Prandoni, M. Sartori, A. Visonà, E. Bigagli, G. Palareti   +12 more
semanticscholar   +1 more source

Edoxaban: an update on the new oral direct factor Xa inhibitor. [PDF]

, 2014
Edoxaban is a once-daily oral anticoagulant that rapidly and selectively inhibits factor Xa in a concentration-dependent manner. This review describes the extensive clinical development program of edoxaban, including phase III studies in patients with ...
A. John Camm, AC Skanes, AG Turpie, AJ Camm, AK Kakkar, AT Cohen, B Laulicht, BF Gage, BI Eriksson, BI Eriksson, BI Eriksson, BI Eriksson, BS Stambler, C Kearon, CB Granger, CT Ruff, DE Salazar, G Agnelli, G Agnelli, G Lu, G Raskob, G Raskob, H Masumoto, H Zahir, Henri Bounameaux, J Mendell, J Mendell, J Mendell, J Mendell, J Mendell, J Mendell, J Stampfuss, JH Alexander, JI Weitz, JL Mega, K Ogata, KL Furie, LT Grip, M Crowther, M Hori, M Pirmohamed, MR Lassen, MR Lassen, MR Lassen, MR Lassen, MR Patel, MS Bathala, MU Zafar, N Chung, N Matsushima, R Caterina De, R Caterina De, RP Giugliano, S Kaatz, S Schulman, S Schulman, S Schulman, SE Kimmel, SJ Connolly, SJ Connolly, SJ Connolly, SZ Goldhaber, T Fuji, T Fuji, T Fukuda, T Hulle van der, T Mikkaichi, T Wilke, T Yamashita, TI Verhoef, W Mueck, Y Falck-Ytter, Y Kuroda   +72 more
core   +1 more source

Does aspirin detract from the benefits of mineralocorticoid receptor antagonists in patients with heart failure and a reduced left ventricular ejection fraction? Probably! [PDF]

, 2017
No abstract ...
Aspirin Myocardial Infarction Study Research Group, Baigent, Baigent, Bonaca, Chin, Cleland, Cleland, Cleland, Cleland, Cleland, Cleland, Gelder, Homma, Lewis, Massie, Meune, Michel, Pitt, Pitt, Silva, Solomon, Tweeddale, Zannad, Zannad   +23 more
core   +1 more source

Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome.

Blood, 2018
Rivaroxaban is an effective and safe alternative to warfarin in patients with atrial fibrillation and venous thromboembolism. We tested the efficacy and safety of rivaroxaban compared with warfarin in high-risk patients with thrombotic antiphospholipid ...
V. Pengo, G. Denas, G. Zoppellaro, S. Jose, A. Hoxha, A. Ruffatti, L. Andreoli, A. Tincani, Caterina Cenci, D. Prisco, T. Fierro, P. Gresele, A. Cafolla, V. De Micheli, A. Ghirarduzzi, A. Tosetto, A. Falanga, I. Martinelli, S. Testa, D. Barcellona, M. Gerosa, A. Banzato   +21 more
semanticscholar   +1 more source